Spinout from Nobel-winning Berkeley lab cuts cancer cell therapy deal with drug giant AbbVie

Vor Biopharma Inc. , the Massachusetts-based cell therapy company focused on cancer treatments, said Friday that its upsized initial public offering priced at the top of the expected ran.....»»

S.....»»

Shares of Myovant Sciences soared 20% in premarket trade Monday, after its parent Sumitovant Biopharma said Myovant wi.....»»

Shares of Myovant Sciences soared 16% in premarket trade Monday, after its parent Sumitovant Biopharma said .....»»

Merck & Co Inc on Tuesday posted a 10.4% rise in first-quarter profit, helped by strong sales of cancer therapy Keytruda, but the drugmaker lowered its 2020 profit forecast due to uncertainty from the COVID-19 pandemic......»»

Aiming to accelerate treatments against COVID-19 into mid-stage clinical trials in three to five months, Vir Biotechnology Inc. said Monday that it signed a collaboration with drug giant GlaxoSmithKline that includes a $250 million equity stake in t.....»»

Fate Therapeutics Inc (NASDAQ: FATE) shares are trading higher on Friday, after a multi-billion dollar deal with Janssen Biotech to develop cell therapies for the treatment of cancer. read more.....»»

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2) BELLUS Health Inc (NASDAQ: BLU) read more.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Context Therapeutics, a Philadelphia biopharmaceutical company focused on hormone-driven cancers, is teaming up with a Chinese biotech firm to advance the development of Context's lead new drug candidate. That experimental therapy, called onapristo.....»»

The deal is the latest to add to Gilead's presence in cancer immunotherapy, an approach to treating cancer that harnesses the body's immune system......»»

HP Inc. claims it is open to talking to copier giant Xerox about some sort of a merger deal, but it is also embarking on a costly stock buyback plan in the hopes of winning over its investors in an upcoming proxy fight......»»

Aduro Biotech Inc. will cut nearly 60% of its workforce and close its European office a month after Swiss partner Novartis AG stepped away from a four-year cancer drug collaboration. The Berkeley company (NASDAQ: ADRO) said the restructuring would cut.....»»

A young biotech startup hoping to map out the actions of cells throughout the body has signed its second major drug development partner with biotech giant Biogen......»»

Roche Holding AG made its second major gene therapy deal in a year on Monday, spending $1.15 billion to obtain the rights to Sarepta Therapeutics Inc's investigational drug to treat duchenne muscular dystrophy (DMD) outside the United States......»»

The Food and Drug Administration on Wednesday approved Padcev as a treatment for metastatic urothelial cancer. The therapy is jointly being developed by Astellas Pharma Inc.....»»

Seattle Genetics, Inc. (NASDAQ: SGEN) shares are advancing following an early approval for Padcev, an antibody conjugate therapy it is co-developing with Astellas Pharma Inc. (OTC: ALPMY). Latest Ratings for SGEN DateFirmAct.....»»

A handful of sickle cell disease treatments and CAR-T therapies that treat cancer have been approved by the Food and Drug Administration in recent years, but a new crop of investigational therapies that would grow those markets is exciting investors......»»

Judy Chou will go from a multinational company that made everything from aspirin to hemophilia A treatments to a smaller company with multiple drugs in clinical trials......»»

The South San Francisco company's drug, currently in an early-phase clinical trial, targets types of breast and lung cancers as well as gastric cancer, which Asian drug makers are anxious to tackle......»»